Pharmaceutical Law & Industry Report® Index-Summary

WARNINGS

See also LABELS AND PACKAGING; SAFETY
– Exjade, 257
– Invirase-Norvir and abnormal heart rhythms, 253
– LABAs, FDA warning on risks, 246
– Prempro

See PREMPRO

– Prostate drugs and diabetes, 1353

WASHINGTON

– Rate cuts for Medicaid challenge (W.D. Wash.), 484
– Walgreens Medicaid decision postponement, 213; will stop filing prescriptions, 399

WEIGHT LOSS PRODUCTS AND PROGRAMS

– Contrave

See CONTRAVE

– Liver damage reports, 724
– Lorcaserin application, 24; goal review date, 294; more data sought, 1378; resubmission, 1632
– Meridia

See MERIDIA

– Qnexa

See QNEXA

– Redux

See REDUX

– Repose law bars product liability claim (U.S., rev den), 418

WELCHOL

– Diabetes generic challenge (D. Del.), 1504

WELLBUTRIN

– Antidepressant side effects, no preemption (E.D. Pa.), 745; failure-to-warn claim, 854
– Antitrust

– – Direct purchaser rep dismissal (E.D. Pa.), 984
– – Indirect purchaser suit (E.D. Pa.), 1215

– Generics

– – Approval, 501; new strengths, 965
– – Sham patent litigation alleged (E.D. Pa.), 1179; reconsideration denied, 1431

WOMEN'S HEALTH

– Elagolix, 794
– HRT

WORKERS COMPENSATION

– Mass., overcharges settlement (Mass. Super. Ct.), 1156